Abbott gets rights to Enanta's HCV protease inhibitors
Enanta Pharmaceuticals licensed Abbott exclusive worldwide rights to develop and commercialize NS3 and NS3/4A protease inhibitors against hepatitis C virus. Abbott receives IP and US patent rights related to various compounds as well as access to Enanta's drug discovery expertise.
- Includes Equity
- Includes Royalty or Profit Split Information
- R&D and Marketing (Licensing)
Please contact Sales at: (212) 520-2765 or email [email protected]
All set! This article has been sent to firstname.lastname@example.org.
All fields are required. For multiple recipients, separate email addresses with a semicolon.